Optimizing the position and use of omalizumab for severe persistent allergic asthma using cost-effectiveness analysis.

Abstract

BACKGROUND There has been some controversy on whether the costs of omalizumab outweigh its benefits for severe persistent allergic asthma. OBJECTIVES This study aimed to resolve the uncertainties and limitations of previous analyses and establish the cost-effectiveness of omalizumab under the list price and Patient Access Scheme (PAS) discounted price for… (More)
DOI: 10.1016/j.jval.2014.07.009

Topics

6 Figures and Tables

Cite this paper

@article{Faria2014OptimizingTP, title={Optimizing the position and use of omalizumab for severe persistent allergic asthma using cost-effectiveness analysis.}, author={Rita Faria and Claire McKenna and Stephen Palmer}, journal={Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research}, year={2014}, volume={17 8}, pages={772-82} }